Skip to content

company profile

Amarin Corporation plc is a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health. Amarin's product development program leverages its extensive experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. This focus includes a commitment to providing grants to support research and education in the disease state including the funding of an ongoing outcomes trial.

Vascepa® (icosapent ethyl), Amarin's first FDA-approved product, is an ultra-pure, EPA-only omega-3 fatty acid product available by prescription. For more information about Vascepa visit For more information about Amarin visit

In July 2012, Vascepa received FDA approval in the United States for use as an adjunct to diet to reduce triglyceride levels in adult patients with severe (≥500 mg/dL) hypertriglyceridemia and is now available by prescription. The triglyceride lowering effect of Vascepa® is not associated with increases in LDL-C, bad cholesterol. The only reported adverse reaction with an incidence >2% and greater than placebo in Vascepa treated patients was arthralgia (2.3% for Vascepa vs. 1.0% for placebo).

If you are reporting an adverse event or product complaint, please email or call the Amarin Call Center at 1 855 VASCEPA.

» See important safety information about Vascepa
» See full prescribing information for Vascepa

Amarin is conducting a cardiovascular outcomes study designed to evaluate the efficacy of Vascepa® in reducing cardiovascular events in a high-risk patient population on statin therapy called the REDUCE-IT trial.

Amarin is headquartered in Dublin, Ireland. In the U.S., the company's office is in Bedminster, New Jersey. Amarin is listed in the U.S. on NASDAQ (symbol: "AMRN").


May Investor Presentation May 2017 1.9 MB Add to Briefcase
Events &

Corporate Governance

The Board of Directors of Amarin Corporation plc (the "Company") sets high standards for the Company's employees, officers and directors. Implicit in this philosophy is the importance of sound corporate governance. It is the duty of the Board of Directors to serve as a prudent fiduciary for shareholders and to oversee the management of the Company's business. To fulfill its responsibilities and to discharge its duty, the Board of Directors follows the procedures and standards that are set forth in these guidelines. These guidelines are subject to modification from time to time as the Board of Directors deems appropriate in the best interests of the Company or as required by applicable laws and regulations.

Document View
Audit Committee Charter
Remuneration Committee Charter
Nominating and Corporate Governance Committee Charter
Code of Business Conduct and Ethics
Memorandum and Articles of Association
CA Declaration 2016
ADR List for 2017
= add file to Briefcase

Related Links

» Executive Team
» Board Of Directors

annual meeting materials

Mar 1, 2017
Form 10-K

Apr 21, 2017
Proxy 2017

Financial Information

Here you will find a summary of Amarin Corporation plc's latest financial information.

Latest Earnings   Format Size  
First Quarter Financial Results   N/A  
Latest Annual Report Date Filed Format Size  
Form 10-K Mar 1, 2017     1.1 MB
Latest Proxy Date Filed Format Size  
Proxy Statement Apr 21, 2017   579.4 KB
AMCO Statutory Accounts Date Filed Format Size  
2016 AMCO Statutory Accounts Apr 14, 2017 1.3 MB
= add file to Briefcase

Financial Links

» SEC Filings
» Annual Reports
» Quarterly Results

Stock Information

Stock Quote (AMRN)

2.98 -0.07  (-2.295%)
4:00 PM ET on May 26, 2017
Previous Close 3.05
Open 3.05
Volume 779,633
Exchange NASDAQ
Day High 3.08
Day Low 2.96
52-Week High 3.65
52-Week Low 1.87

Stock Chart

Stock Chart
Stock price graph

The stock information provided is for informational purposes only and is not intended for trading purposes. The stock information is provided by eSignal, stock charts are provided by EDGAR Online, both third party services, and Amarin Corporation plc does not maintain or provide information directly to this service. Stock information is delayed approximately 20 minutes.

Sign up for email alerts.

The stock information provided is for informational purposes only and is not intended for trading purposes. The stock information is provided by eSignal, stock charts are provided by NASDAQ OMX, both third party services, and Amarin Corporation plc does not maintain or provide information directly to this service. Stock information is delayed approximately 20 minutes.

Investor FAQs


Please click here

Please see the attached document for a detailed response. This information is intended for communication with investors and should not be construed as marketing the use of any Amarin products or product candidates. Click Here.

Amarin is pleased to announce the publication of “Rationale and Design of REDUCE-IT: Reduction of Cardiovascular Events with Icosapent Ethyl – Intervention Trial” in the March issue of Clinical Cardiology.

The article can be accessed here. Also, an Amarin press release has been issued related to this publication.

The following are key points regarding the study design for REDUCE-IT:

REDUCE-IT: Study Design

  • REDUCE-IT is a landmark global study involving approximately 8,000 patients
  • It is a randomized, multicenter, double-blind, placebo-controlled study designed to determine if treatment with VASCEPA® 4 g/day versus placebo reduces major adverse cardiovascular events (MACE) in statin-treated patients with persistent hypertriglyceridemia and high cardiovascular risk
  • The primary endpoint of the study is the time to the first occurrence of the composite endpoint of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, coronary revascularization, or hospitalization for unstable angina
  • Secondary endpoints include time to event analyses of components of the primary endpoint
  • The study is being conducted under a special protocol assessment agreement with the FDA

In September 2014, the National Lipid Association (NLA) launched a nationwide triglyceride campaign during National Cholesterol Education Month. The NLA's announced goal is to encourage patient education and drive discussions about lipid management and the consequences of high cholesterol and triglyceride levels.

According to the NLA, the mission of the campaign is to encourage physicians to inform patients about the importance of proper treatment and prevention as it relates to their entire lipid profile - not just cholesterol, but elevated triglyceride levels, too.

"We want to raise awareness around elevated triglycerides with patients and health care providers alike, as they may unsuspectingly affect patients' health, even if they look and feel healthy," said NLA President Terry A. Jacobson, MD. "Fortunately, health care providers are committed to offering their patients their best care, and we're committed to ensuring they have the tools to do so."

In a recent survey of health care providers, the NLA discovered a need for standard protocols surrounding the measure of patients' total lipid profiles, including triglycerides. To jumpstart these educational and preventive efforts, the NLA urges health care providers to compare patients' triglyceride levels to the following categories:

With this campaign, NLA hopes to provide the necessary resources for clinical practice and education, as well as generate awareness about lipid management.

Amarin is not responsible for the content of NLA's campaign.

On March 31, 2014, Amarin executed a co-promotion agreement with Kowa under which Kowa will help educate physicians in the U.S. on the use of Vascepa.  The initial term of the agreement extends through the end of 2018.  Kowa has a successful track record of launching and commercializing drugs for the treatment of cardiovascular disease in the United States, including its flagship statin product, LIVALO® (pitavastatin).  Kowa’s sales team, which consists of approximately 250 sales representatives, is expected to be trained with respect to Vascepa during May 2014 and thereafter begin Vascepa co-promotion with Amarin’s sales representatives based on a plan designed to substantially increase both the number of sales targets reached and the frequency of sales calls on existing sales targets.  The arrangement is designed to enable Amarin to more than double its early 2014 sales calls levels. Kowa is responsible for the cost of its sales representatives and related promotional materials.  Amarin will compensate Kowa with a co-promotion fee based on a percentage of Vascepa gross margins that increase during the agreement’s term, from the high single digits in 2014 to the low twenty percent levels in 2018, subject to certain adjustments.

Amarin's ordinary shares, represented by American Depositary Shares, are listed on the NASDAQ Capital Market under the ticker AMRN.

Until July 16th 2008, Amarin's ordinary shares were also listed on London's AIM (ticker: AMRN) and Dublin's IEX (ticker: H2E).

An American Depositary Share (ADS) is a security that represents an ownership interest in the shares of a foreign company trading on a U.S. securities market. The shares represented by the ADSs are held by a U.S. depositary bank and are evidenced by certificates called American Depositary Receipts (ADRs), although the terms ADS and ADR are often used interchangeably. ADRs enable U.S. investors to buy shares in foreign companies without undertaking cross-border transactions (i.e., in U.S. dollars), and they trade, clear and settle in accordance with U.S. market regulations and conventions.

Non-U.S. companies whose securities trade on a U.S. securities market.

One Amarin ADR equals one Amarin ordinary share.

Holders of ADRs may authorize Citibank, Amarin's Depositary, to act as a proxy in exercising voting rights according to the number of ordinary shares represented by their respective ADRs.

Amarin's fiscal year is the 12-month calendar year ending December 31st.

Please visit our website at where you can read more on our executive team, board of directors, company strategy, corporate governance, therapeutic focus, product pipeline and partnering activities.

Amarin is headquartered in Dublin, Ireland.

Amarin's financial statements, including annual reports, can be found on Amarin's website in the Investor Relations section here. Alternatively, you can find all of Amarin's filings with the U.S. Securities and Exchange Commission under the SEC Filings section of the website here.

The U.S. Transfer Agent for Amarin's ADS holders is:

Citibank Shareholder Services
P.O. Box 43077
Providence, RI 02940-5000
Tel: +1-877-248-4237

The Registrar for Amarin's ordinary shares is:

Citi - Depositary Receipt Services
388 Greenwich Street
14th Floor
New York, NY 10013


PO Box 4630,
Aspect House,
Spencer Road,
Lancing, West Sussex,
BN99 6QQ, England
Telephone: +44 121 415 7047

The Depositary for Amarin's ADRs is:

Citibank Shareholder Services
P.O. Box 43077
Providence, RI 02940-5000
Tel: +1-877-248-4237 Fax: +1-201-324-3284

Ernst & Young LLP

99 Wood Avenue South

Iselin, NJ 08830

You can register to receive updates announced by Amarin by submitting your email address on the Mailing List section of our website, which option can be found on each page of the website Alternatively you can send an email to requesting to be notified of any new updates announced

Please contact: Elisabeth Schwartz
Telephone (U.S.): 908-719-1315

Please submit your question using the form below.

Contact Form
* Indicates required field